ITI-214 Safe, Well-tolerated in Mild to Moderate Parkinson’s Patients, Phase 1/2 Trial Shows


Treatment with the experimental oral therapy ITI-214 was safe and well-tolerated in patients with mild to moderate Parkinson’s disease, according to a Phase 1/2 clinical trial.

Trial findings also suggested that ITI-214 may ease motor symptoms in these patients.

The study, “A Phase I/II Clinical Study of  ITI-214, a Novel Phosphodiesterase-I (PDE1) Inhibitor, for the Treatment of Parkinson’s Disease (PD),” was presented during AD/PD 2019 — The 14th International Conference on Alzheimer’s and Parkinson’s Diseases, taking place March 26-31 in Lisbon, Portugal.

ITI-214 is a selective blocker of an enzyme called phosphodiesterase 1 (PDE1), implicated in the breakdown of cAMP and cGMP. These two messenger molecules act within cells of the nervous system in response to diverse signals. Because altered PDE1 activity has been reported in both neurological and cardiovascular diseases, blockers such as ITI-214 are intended to restore its normal function.

Work in rodent models suggested that ITI-214, being developed by Intra-Cellular Therapies, may relieve motor and non-motor symptoms of Parkinson’s. In preclinical studies, the investigational therapy also reduced neuroinflammation through its effect on microglia — key immune cells in the central nervous system — and prevented neurodegeneration.

Data from four Phase 1 trials in healthy volunteers showed that treatment with ITI-214 was generally well-tolerated and safe.

Researchers are now presenting clinical data from the randomized, double-blind, placebo-controlled Phase 1/2 trial (NCT03387215) that primarily evaluated the safety and tolerability of increasing doses of ITI-214 in patients with mild to moderate Parkinson’s.

As secondary goals, the seven-day Intra-Cellular Therapies-sponsored study assessed the compound’s pharmacokinetics — its absorption, distribution, metabolism, and excretion in the body — as well as biomarkers of inflammation, and motor and non-motor effects through the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale.

The 40 participants (50 years and older) were maintained on stable Parkinson’s therapy. All five doses of ITI-214 — 1, 3, 10, 30, and 90 mg — were found safe and generally well-tolerated. In addition, the findings showed signals of less motor dysfunction and dyskinesia — involuntary, jerky movements — with some of the administered doses.

“Clinical data indicate that ITI-214 is safe and generally well tolerated across a range of doses in patients with mild to moderate [Parkinson’s],” the scientists wrote.

Noting that the signals of clinical improvement warrant further evaluation, the team added that “selective PDE1 inhibition may represent a novel approach for the treatment of motor and non-motor symptoms associated with [Parkinson’s].”

Of note, all seven of the study’s authors are employees of Intra-Cellular.

Besides Parkinson’s, ITI-214 is being evaluated in a Phase 1/2 trial (NCT03387215) in patients with heart failure, which is supported by results showing increased heart contraction strength in dogs and rabbits.

The post ITI-214 Safe, Well-tolerated in Mild to Moderate Parkinson’s Patients, Phase 1/2 Trial Shows appeared first on Parkinson’s News Today.

Potential Parkinson’s Therapy ITI-214 May Also Treat Heart Failure, Animal Study Suggests

heart failure, ITI-214

An investigational compound called ITI-214, which is being investigated in clinical trials for Parkinson’s disease, may also be effective in strengthening the heart, according to an animal study recently published in the journal Circulation.

ITI-214, being developed by Intra-Cellular Therapies, is a potent and selective inhibitor of an enzyme known as phosphodiesterase 1 (PDE1), which mediates the breakdown of cAMP and cGMP. These messenger molecules act within the cells of the nervous system in response to various signals, but they also play an important role in cardiac myocytes, a cell type found in the heart muscle.

Changes in PDE1 activity have been reported in both neurological and cardiovascular diseases, and the use of PDE1 inhibitors is intended to block the breakdown of cAMP and cGMP to re-establish normal function in these conditions.

An ongoing Phase 1/2 trial (NCT03257046) is evaluating ITI-214’s safety, tolerability, and pharmacological profile in Parkinson’s patients. Participants are still being recruited, for an estimated total of 40 patients. The trial is expected to conclude sometime this month.

ITI-214 is also being tested in a Phase 1/2 clinical trial (NCT03387215) in patients with heart failure at Johns Hopkins Medicine and Duke University. The compound successfully passed Phase 1 safety trials in healthy individuals.

Heart failure develops as a result of the heart becoming weakened or stiff, which may lead to inefficient ability to pump blood to the rest of your body. Although patients may benefit from available medications that boost the strength of cardiac contractions — such as dobutamine — these therapies may lead to an irregular heartbeat and other complications.

Prior studies have shown that PDE1 inhibitors can ease the abnormally thick heart muscle in mice. However, because mice have a different form of PDE1 than humans, PDE1 inhibitors may cause different effects. Based on this, Johns Hopkins Medicine researchers in this study used dogs and rabbits, which have a PDE1 composition more similar to humans.

The dogs underwent surgeries to implant sensors and pacemakers. The effects of different doses of ITI-214, both oral and intravenous, were tested before and after inducing heart failure.

Results showed that oral ITI-214 at 10 mg per kilogram of body weight increased the amount of blood pumped out by the heart per minute by 50% in healthy hearts and by 32% in failing hearts. This was associated with a nearly 30% increase in the strength of the heart’s contractions with blood vessels dilation. Intravenous ITI-214 had similar but more rapid effects.

“To my knowledge, no study had reported increased heart contraction strength from a PDE1 inhibition before,” David Kass, MD, the study’s senior author, said in a press release. He also noted that the similar composition of PDE-1 in larger mammals and humans may have led to the positive results.

Kass added that ITI-214 also raised the heart rate of healthy dogs by approximately 40 beats per minute, which may be dangerous for heart failure patients. However, dogs with failing hearts did not show an ITI-214-induced change in heart rate.

Importantly, the strengthened heart contractions were not linked to the development of irregular heartbeats, as observed with dobutamine and inhibitors of a different PDE — PDE3 — such as Primacor (milrininone).

Since ITI-214 produced many of the same effects as PDE3 inhibitors, the investigators tested them side by side, Kass said.

Comparisons in isolated muscle cells from rabbit hearts showed that both PDE3 inhibitors and ITI-214 caused the cells to contract more strongly. However, unlike PDE3 inhibitors, ITI-214 did not increase calcium levels, suggesting a different mechanism that may spare the severe alterations in heartbeat.

“Our results are intriguing because so far it’s been largely uncharted territory to come up with a way of increasing contractility that doesn’t ultimately hurt patients,” Kass said.

The post Potential Parkinson’s Therapy ITI-214 May Also Treat Heart Failure, Animal Study Suggests appeared first on Parkinson’s News Today.

Source: Parkinson's News Today